A strategic approach to COVID-19 vaccine R&D

• Published in: Science Vol. 368; no. 6494; pp. 948 - 950
• Main Authors: Corey, Lawrence, Mascola, John R, Fauci, Anthony S, Collins, Francis S
• Format: Journal Article Web Resource
• Language: English
• Published: United States 29.05.2020
• Subjects: Adjuvants, Immunologic; Animals; Betacoronavirus - immunology; Clinical Trial Protocols as Topic; Clinical Trials as Topic; Coronavirus Infections - immunology; Coronavirus Infections - prevention & control; COVID-19; COVID-19 Vaccines; Disease Models, Animal; Humans; Immunogenicity, Vaccine; International Cooperation; National Institutes of Health (U.S.); Pandemics - prevention & control; Pneumonia, Viral - immunology; Pneumonia, Viral - prevention & control; Public-Private Sector Partnerships; RNA, Messenger; SARS-CoV-2; Spike Glycoprotein, Coronavirus - immunology; T-Lymphocytes - immunology; United States; Vaccines, DNA; Vaccines, Synthetic - immunology; Viral Vaccines - adverse effects; Viral Vaccines - immunology; United States

A public-private partnership and platform for harmonized clinical trials aims to accelerate licensure and distribution There is an unprecedented need to manufacture and distribute enough safe and effective vaccine to immunize an extraordinarily large number of individuals in order to protect the ent...